News

Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded dosing schedule of EBGLYSS® (lebrikizumab-lbkz), allowing eligible patients…
Read More...

Pfizer has secured an expanded approval from the U.S. Food and Drug Administration (FDA) for HYMPAVZI® (marstacimab-hncq), broadening access to the once-weekly treatment for additional…
Read More...

Johnson & Johnson has agreed to acquire biotechnology company Firefly Bio, Inc. in a deal valued at $1 billion in cash, strengthening its oncology pipeline with a novel platform…
Read More...

Incyte has announced a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal valued at $1.25 billion upfront, with the potential…
Read More...

Owkin and Sanofi have announced a new multi-year collaboration aimed at accelerating drug discovery and development through advanced artificial intelligence technologies. The agreement…
Read More...

Novo Nordisk has announced that its oral obesity treatment, Wegovy® (semaglutide) tablets 25 mg, has surpassed three million prescriptions in the United States within just over five…
Read More...

Alnylam Pharmaceuticals and Inceptive Nucleics have entered into a strategic collaboration valued at up to $2 billion aimed at accelerating the development of next-generation RNA-based…
Read More...

Lonza and Stipple Bio have entered into a multi-target licensing agreement aimed at accelerating the development of next-generation antibody-drug conjugate (ADC) therapies for cancer,…
Read More...

Biogen has received a significant regulatory boost for its investigational spinal muscular atrophy (SMA) therapy salanersen after the U.S. Food and Drug Administration (FDA) granted the…
Read More...

Chai Discovery has entered into a licensing agreement with pharmaceutical giant Pfizer, marking a significant step in the growing adoption of artificial intelligence technologies across…
Read More...

Cellares and TScan Therapeutics have entered into a strategic agreement to evaluate automated clinical manufacturing of TSC-101, an investigational T cell receptor-engineered T cell…
Read More...

Massive Bio and Optellum have announced a strategic collaboration designed to connect early lung cancer detection with faster access to clinical trials, potentially addressing one of…
Read More...

Roche has moved a step closer to bringing a potential new treatment option to patients with early-stage breast cancer after the U.S. Food and Drug Administration (FDA) accepted the…
Read More...

AbbVie has secured a significant regulatory milestone in Europe after the European Commission approved AQUIPTA® (atogepant) for the acute treatment of migraine in adults, providing…
Read More...

Contraline, a clinical-stage biopharmaceutical company focused on developing innovative male contraceptives, has secured $92.5 million in Series B financing to advance the late-stage…
Read More...

CytomX Therapeutics has expanded its collaboration and licensing agreement with Regeneron Pharmaceuticals to advance the development of next-generation bispecific cancer therapies,…
Read More...

Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib, an…
Read More...

SystImmune and Bristol Myers Squibb have reported positive Phase 3 results for izalontamab brengitecan (iza-bren), an investigational bispecific antibody-drug conjugate (ADC),…
Read More...

Vertex Pharmaceuticals has moved a step closer to bringing a new treatment option to patients with immunoglobulin A nephropathy (IgAN) after the U.S. Food and Drug Administration (FDA)…
Read More...

Agios Pharmaceuticals has strengthened its position in rare hematology by securing exclusive global rights to cevidoplenib, a next-generation oral spleen tyrosine kinase (SYK)…
Read More...